Lacosamide for the treatment of diabetic neuropathic pain

References

• Cole BE. Diabetic peripheral neuropathic pain: recognition and management. Pain Med.8(Suppl. 2), S27–S32 (2007).
   PubMed Web of Science ®Google Scholar
• Diabetic peripheral neuropathic pain. Consensus guidelines for treatment. J. Fam. Pract. (Suppl.) 3–19 (2006).
   Google Scholar
• Boulton AJ, Vinik AI, Arezzo JC et al. Diabetic neuropathies: a statement by the American Diabetes Association. Diabetes Care28(4), 956–962 (2005).
   PubMed Web of Science ®Google Scholar
• Galer BS, Gianas A, Jensen MP. Painful diabetic polyneuropathy: epidemiology, pain description, and quality of life. Diabetes Res. Clin. Pract.47(2), 123–128 (2000).
   PubMed Web of Science ®Google Scholar
• Cymbalta® (duloxetine hydrochloride) delayed-release capsules prescribing information. Eli Lilly and Company, Indianapolis, IN, USA (2007).
   Google Scholar
• Lyrica® (pregabalin) prescribing information. Pfizer Inc. New York, NY, USA (2007).
   Google Scholar
• Attal N, Cruccu G, Haanpaa M et al. EFNS guidelines on pharmacological treatment of neuropathic pain. Eur. J. Neurol.13(11), 1153–1169 (2006).
   PubMed Web of Science ®Google Scholar
• Dworkin RH, Backonja M, Rowbotham MC et al. Advances in neuropathic pain: diagnosis, mechanisms, and treatment recommendations. Arch. Neurol.60(11), 1524–1534 (2003).
   PubMed Web of Science ®Google Scholar
• Moulin DE, Clark AJ, Gilron I et al. Pharmacological management of chronic neuropathic pain – consensus statement and guidelines from the Canadian Pain Society. Pain Res. Manag.12(1), 13–21 (2007).
   PubMed Web of Science ®Google Scholar
• Dworkin RH, O’Connor AB, Backonja M et al. Pharmacologic management of neuropathic pain: evidence-based recommendations. Pain132(3), 237–251 (2007).
   PubMed Web of Science ®Google Scholar
• Argoff CE, Backonja MM, Belgrade MJ et al. Consensus guidelines: treatment planning and options. Diabetic peripheral neuropathic pain. Mayo Clin. Proc.81(4 Suppl.), S12–S25 (2006).
   Google Scholar
• Choi D, Stables JP, Kohn H. Synthesis and anticonvulsant activities of N-benzyl-2-acetamidopropionamide derivatives. J. Med. Chem.39(9), 1907–1916 (1996).
   PubMed Web of Science ®Google Scholar
• Beyreuther BK, Freitag J, Heers C, Krebsfanger N, Scharfenecker U, Stohr T. Lacosamide: a review of preclinical properties. CNS Drug. Rev.13(1), 21–42 (2007).
   PubMedGoogle Scholar
• Errington AC, Stohr T, Heers C, Lees G. The investigational anticonvulsant lacosamide selectively enhances slow inactivation of voltage-gated sodium channels. Mol. Pharmacol.73(1), 157–169 (2008).
   PubMed Web of Science ®Google Scholar
• Sheets PL, Heers C, Stoehr T, Cummins TR. Differential block of sensory neuronal voltage-gated sodium channels by lacosamide [(2R)-2-(acetylamino)-N-benzyl-3-methoxypropanamide], lidocaine, and carbamazepine. J. Pharmacol. Exp. Ther.326(1), 89–99 (2008).
   PubMed Web of Science ®Google Scholar
• Greene ND, Bamidele A, Choy M et al. Proteome changes associated with hippocampal MRI abnormalities in the lithium pilocarpine-induced model of convulsive status epilepticus. Proteomics7(8), 1336–1344 (2007).
   Google Scholar
• Ryu MJ, Lee C, Kim J, Shin HS, Yu MH. Proteomic analysis of stargazer mutant mouse neuronal proteins involved in absence seizure. J. Neurochem.104(5), 1260–1270 (2008).
   Google Scholar
• Katano T, Mabuchi T, Okuda-Ashitaka E, Inagaki N, Kinumi T, Ito S. Proteomic identification of a novel isoform of collapsin response mediator protein-2 in spinal nerves peripheral to dorsal root ganglia. Proteomics6(22), 6085–6094 (2006).
   PubMedGoogle Scholar
• Czech T, Yang JW, Csaszar E, Kappler J, Baumgartner C, Lubec G. Reduction of hippocampal collapsin response mediated protein-2 in patients with mesial temporal lobe epilepsy. Neurochem. Res.29(12), 2189–2196 (2004).
   PubMed Web of Science ®Google Scholar
• Koester J, Siegelbaum SA. Propagated signaling: the action potential. In: Principles of Neural Science (4th Edition). Kandel ER, Schwartz JH, Jessell TM (Eds). McGraw-Hill, New York, NY, USA 150–170 (2000).
   Google Scholar
• Freitag J, Beyreuther B, Heers C, Stohr T. Lacosamide modulates collapsin response mediator protein 2 (CRMP-2) (Abstract). Neurology68(12 Suppl. 1), A125 (2007).
   Google Scholar
• Stöhr T, Krause E, Selve N. Lacosamide displays potent antinociceptive effects in animal models for inflammatory pain. Eur. J. Pain.10(3), 241–249 (2006).
   PubMed Web of Science ®Google Scholar
• Beyreuther B, Callizot N, Stohr T. Antinociceptive efficacy of lacosamide in a rat model for painful diabetic neuropathy. Eur. J. Pharmacol.539(1–2), 64–70 (2006).
   PubMed Web of Science ®Google Scholar
• Stöhr TBB, Selve N. Lacosamide displays potent antinociceptive effects in animal models for neuropathic pain and inflammatory pain. Presented at: 11th World Congress on Pain. Sydney, Australia, 21–26 August 2005.
   Google Scholar
• Beyreuther BK, Callizot N, Brot MD, Feldman R, Bain SC, Stohr T. Antinociceptive efficacy of lacosamide in rat models for tumor- and chemotherapy-induced cancer pain. Eur. J. Pharmacol.565(1–3), 98–104 (2007).
   PubMed Web of Science ®Google Scholar
• Hao JX, Stohr T, Selve N, Wiesenfeld-Hallin Z, Xu XJ. Lacosamide, a new anti-epileptic, alleviates neuropathic pain-like behaviors in rat models of spinal cord or trigeminal nerve injury. Eur. J. Pharmacol.553(1–3), 135–140 (2006).
   PubMed Web of Science ®Google Scholar
• Beyreuther B, Callizot N, Stohr T. Antinociceptive efficacy of lacosamide in the monosodium iodoacetate rat model for osteoarthritis pain. Arthritis Res. Ther.9(1), R14 (2007).
   PubMed Web of Science ®Google Scholar
• Beyreuther BK, Geis C, Stohr T, Sommer C. Antihyperalgesic efficacy of lacosamide in a rat model for muscle pain induced by TNF. Neuropharmacology52(5), 1312–1317 (2007).
   PubMed Web of Science ®Google Scholar
• Ben-Menachem E. Lacosamide: an investigational drug for adjunctive treatment of partial-onset seizures. Drugs Today (Barc.)44(1), 35–40 (2008).
   PubMed Web of Science ®Google Scholar
• Bialer M, Johannessen SI, Kupferberg HJ, Levy RH, Loiseau P, Perucca E. Progress report on new antiepileptic drugs: a summary of the Sixth Eilat Conference (EILAT VI). Epilepsy Res.51(1–2), 31–71 (2002).
   PubMed Web of Science ®Google Scholar
• Horstmann R, Bonn R, Cawello W, Doty P, Rudd GD. Basic clinical pharmacologic investigations of the new antiepileptic drug SPM 927 (Abstract). Epilepsia43(Suppl. 7), 188 (2002).
   Google Scholar
• Bialer M, Johannessen SI, Kupferberg HJ, Levy RH, Perucca E, Tomson T. Progress report on new antiepileptic drugs: a summary of the Eighth Eilat Conference (EILAT VIII). Epilepsy Res.73(1), 1–52 (2007).
   PubMed Web of Science ®Google Scholar
• Bialer M, Johannessen SI, Kupferberg HJ, Levy RH, Perucca E, Tomson T. Progress report on new antiepileptic drugs: a summary of the Seventh Eilat Conference (EILAT VII). Epilepsy Res.61(1–3), 1–48 (2004).
   PubMed Web of Science ®Google Scholar
• Thomas D, Scharfenecker U, Nickel B et al. Lacosamide has low potential for drug-drug interaction. Presented at: American Pain Society 26th Annual Scientific Meeting. Washington, DC, USA, May 2–5 2007.
   Google Scholar
• Doty P, Rudd GD, Stoehr T, Thomas D. Lacosamide. Neurotherapeutics4(1), 145–148 (2007).
   PubMed Web of Science ®Google Scholar
• Thomas D, Scharfenecker U, Schiltmeyer B, Cawello W, Doty P, Horstmann R. Low potential for drug–drug-interaction of lacosamide (Abstract). J. Pain8(4 Suppl. 1), S39 (2007).
   Google Scholar
• Schiltmeyer B, Cawello W, Kropeit D, Hammes W, Hortsmann R. Pharmacokinetics of the new antiepileptic drug SPM 927 in human subjects with different age and gender (Abstract). Epilepsia46(Suppl. 7), 313 (2004).
   Google Scholar
• Cawello W, Kropeit D, Schiltmeyer B, Hammes W, Horstmann R. Food does not affect the pharmacokinetics of SPM 927. Epilepsia45(Suppl. 7), 307 (2004).
   Web of Science ®Google Scholar
• Fountain NB, Horstmann R, Cawello W, Doty P, Rudd GD. Absence of effect of adjunctive SPM 927 on concomitant AED plasma concentrations in subjects with partial seizures. Epilepsia44(Suppl. 9), 96 (2003).
   Google Scholar
• Horstmann R, Bonn R, Cawello W, Doty P, Rudd GD. SPM 927 does not interact with valproic acid and carbamazepine (Abstract). Epilepsia44(Suppl. 9), 97 (2003).
   Google Scholar
• Jatuzis D, Biton V, Ben-Menachem E, Abou-Khalil B, Doty P, Rudd GD. Evaluation of the effect of oral lacosamide on concomitant AED plasma concentrations in patients with partial seizures (Abstract). Epilepsia46(Suppl. 8), 170 (2005).
   Google Scholar
• Horstmann R, Bonn R, Cawello W, Doty P, Rudd D. Lacosamide does not interact with valproic acid and carbamazepine. Presented at: American Epilepsy Society 57th Annual Meeting. Boston, MA, 5–10 December 2003.
   Google Scholar
• Biton V, Rosenfeld WE, Whitesides J, Fountain NB, Vaiciene N, Rudd GD. Intravenous lacosamide as replacement for oral lacosamide in patients with partial-onset seizures. Epilepsia49(3), 418–424 (2008).
   PubMed Web of Science ®Google Scholar
• Rosenfeld WE, Biton V, Mameniskiene R et al. Pharmacokinetics and safety of intravenous lacosamide administered as replacement for adjunctive oral lacosamide in patients with partial-onset seizures (Abstract). Epilepsia46(Suppl. 8), 184 (2005).
   PubMedGoogle Scholar
• McCleane G, Koch B, Rauschkolb C. Does SPM 927 have an analgesic effect in human neuropathic pain? An open label study. Neurosci. Lett.352(2), 117–120 (2003).
   PubMed Web of Science ®Google Scholar
• McCleane GJ, Koch B, Rauschkolb C. A report of the continuing analgesia after 12 months treatment with SPM 927 in six subjects with neuropathic pain. J. Neuropathic Pain Symptom Palliation1(1), 25–28 (2005).
   Google Scholar
• Rauck RL, Shaibani A, Biton V, Simpson J, Koch B. Lacosamide in painful diabetic peripheral neuropathy: a Phase 2 double-blind placebo-controlled study. Clin. J. Pain23(2), 150–158 (2007).
   PubMed Web of Science ®Google Scholar
• Farrar JT, Young JP Jr, LaMoreaux L, Werth JL, Poole RM. Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale. Pain94(2), 149–158 (2001).
   PubMed Web of Science ®Google Scholar
• Farrar JT, Berlin JA, Strom BL. Clinically important changes in acute pain outcome measures: a validation study. J. Pain Symptom Manage.25(5), 406–411 (2003).
   PubMed Web of Science ®Google Scholar
• Wymer J. A multicenter, randomized, 50 double-blind, placebo-controlled trial assessing the efficacy and safety of lacosamide in painful distal diabetic neuropathy (SP742) (Abstract). Ann. Neurol.60(Suppl. 11), S68 (2006).
   Google Scholar
• Wymer J. Efficacy and safety of lacosamide in painful distal diabetic neuropathy (SP742). Presented at: College of Psychiatric and Neurologic Pharmacists 10th Annual Meeting. Colorado Springs, CO, USA, 15–18 April 2007.
   Google Scholar
• Ziegler D, Bongardt S, Thierfelder S, Koch B. A multicenter, randomized, double-blind, placebo-controlled trial to assess the efficacy and safety of lacosamide in subjects with painful distal diabetic neuropathy (SP743). Presented at: 11th World Congress on Pain. Sydney, Australia, 21–26 August 2005.
   Google Scholar
• Shaibani A, Kenney P, Simpson J, Bongardt S. Lacosamide in painful distal diabetic neuropathy: results of a multi-center, placebo-controlled US trial (SP768) (Abstract). Eur. J. Neurol.14(Suppl. 1), 250 (2007).
   Google Scholar
• Shaibani A, Kenney P, Simpson J, Bongardt S. Lacosamide in subjects with painful distal diabetic neuropathy: results of a multi-center, randomized, double-blind, placebo-controlled, parallel group trial (SP768). Presented at: European Federation of Neurological Societies Annual Meeting. Brussels, Belgium, 25–28 August 2007.
   Google Scholar
• Shaibani A, Bongardt S, Sommerville K, Simpson J. Evaluation of lacosamide in diabetic neuropathic pain trials. Presented at: American Pain Society 27th Annual Scientific Meeting. Tampa, FL, USA, 8–10 May 2008.
   Google Scholar
• UCB. Data presented at AAN show that lacosamide significantly reduced pain and was generally well tolerated in patients with diabetic neuropathic pain (media release) April 16 2008.
   Google Scholar
• Shaibani A, Bongardt S, Sommerville K. Evaluation of lacosamide in diabetic neuropathic pain trials (Abstract). J. Pain9(4), 21 (2008).
   Google Scholar
• Wymer J, Ziegler D, Sommerville K, Bongardt S, Shaibani A. Lacosamide in patients with painful diabetic neuropathy: a summary of adverse events in four double-blind randomized clinical trials. Presented at: The American Academy of Neurology 60th Annual Meeting. Chicago, IL, USA, 12–19 April 2008.
   Google Scholar
• Wymer J, Ziegler D, Sommerville K, Bongardt S, Shaibani A. Lacosamide in patients with diabetic neuropathic pain: a summary of adverse events in four double-blind randomized clinical trials. Presented at: American Diabetes Association 68th Annual Meeting. San Francisco, CA, USA, 6–10 June 2008.
   Google Scholar
• Wymer J, Ziegler D, Sommerville K, Bongardt S, Shaibani A. Safety summary of lacosamide for treatment of diabetic neuropathic pain (Abstract). Diabetes57(Suppl. 1), A158 (2008).
   Google Scholar
• Wymer J, Ziegler D, Sommerville K, Bongardt S. Lacosamide in patients with painful diabetic neuropathy: a summary of adverse events in four double-blind randomized clinical trials (Abstract). Neurology70(Suppl. 1), A163 (2008).
   Google Scholar
• Thomas D, Zisowsky J, Wilhelm D, Horstmann R. Lacosamide demonstrates no potential for QTc-prolongation. Presented at: 9th International Conference on the Mechanisms and Treatment of Neuropathic Pain. Southampton, Bermuda, 2–4 November 2006.
   Google Scholar
• Hidvégi T, Bretschneider M, Thierfelder S, Sommerville K, Bongardt S. Long-term efficacy of lacosamide in subjects with diabetic neuropathic pain: results of a double-blind, randomized withdrawal trial (SP746–1) (Abstract). J. Pain9(4), 27 (2008).
   Google Scholar
• Shaibani A, Biton V, Rauck R, Koch B, Simpson J. Long-term oral lacosamide in painful diabetic neuropathy: a two-year open-label extension trial. Eur. J. Pain. (2008) (Epub ahead of print).
   Google Scholar
• Graf R, Frye W, Simpson J, Jay G. Lacosamide in long-term treatment of painful diabetic neuropathy (SP745). Presented at: European Federation of Neurological Societies Annual Meeting. Brussels, Belgium, 25–28 August 2007.
   Google Scholar
• Graf R, Frye W, Simpson J, Jay G. Lacosamide in long-term treatment of painful diabetic neuropathy (DNP) (SP745) (Abstract). Eur. J. Neurol.14(Suppl. 1), 260 (2007).
   Google Scholar
• Hidvégi T, Bretschneider M, Bongardt S, Koch B. Lacosamide in subjects with painful distal diabetic neuropathy: results of a multi-center, open-label, follow-on trial (SP746). Presented at: American Pain Society 25th Annual Scientific Meeting. San Antonio, TX, USA, 3–6 May 2006.
   Google Scholar
• Bretschneider M, Bongardt S, Koch B. A multi-center, open-label, follow-on trial to assess the long-term safety and efficacy of lacosamide in subjects with painful distal diabetic neuropathy (SP746) (Abstract). J. Pain7(4), S43 (2006).
   Google Scholar
• Simpson K, Tzschaschel B, Bongardt S, Koch B. Lacosamide in patients with painful diabetic neuropathy: one year interim results from a long-term, multi-center, open-label trial (SP830). Presented at: Pain in Europe Congress. Istanbul, Turkey, 13–16 September 2006.
   Google Scholar
• McQuay HJ, Tramer M, Nye BA, Carroll D, Wiffen PJ, Moore RA. A systematic review of antidepressants in neuropathic pain. Pain68(2–3), 217–227 (1996).
   PubMed Web of Science ®Google Scholar
• Low PA, Dotson RM. Symptomatic treatment of painful neuropathy. JAMA280(21), 1863–1864 (1998).
   PubMed Web of Science ®Google Scholar
• Deiderich NJ, Goetz CG. The placebo treatments in neurosciences: new insights from clinical and neuroimaging studies. Neurology71(9), 677–684 (2008).
   Google Scholar
• Apfel SC, Schwartz S, Adornato BT et al. Efficacy and safety of recombinant human nerve growth factor in patients with diabetic polyneuropathy: a randomized controlled trial. rhNGF Clinical Investigator Group. JAMA284(17), 2215–2221 (2000).
   PubMed Web of Science ®Google Scholar
• Ben-Menachem E, Biton V, Jatuzis D, Abou-Khalil B, Doty P, Rudd GD. Efficacy and safety of oral lacosamide as adjunctive therapy in adults with partial-onset seizures. Epilepsia48(7), 1308–1317 (2007).
   PubMed Web of Science ®Google Scholar
• Chung S, Sperling M, Biton V, Krauss G, Beaman M, Hebert D. Lacosamide: efficacy and safety as oral adjunctive treatment for partial-onset seizures (SP754) (abstract). Epilepsia48(Suppl. 6), 321 (2007).
   Web of Science ®Google Scholar
• Halász P, Kälviäinen R, Mazurkiewicz-Beldzinska M, Rosenow F, Doty P, Sullivan T. Lacosamide: efficacy and safety as oral adjunctive therapy in adults with partial seizures (SP755) (Abstract). Epilepsia47(Suppl. 4), 3 (2006).
   Google Scholar